Locations:
Cleveland Clinic Innovations portfolio company, Cleveland Diagnostics, launches its second annual prostate-specific antigen campaign “A PSA on PSA” to raise awareness and education for prostate cancer screening tests.
Cleveland Diagnostics has launched its second annual prostate-specific antigen campaign, "A PSA on PSA," to raise awareness about prostate cancer screening. The campaign, which starts on September 1 and runs in conjunction with Prostate Cancer Awareness Month, includes a fact sheet with information about PSA tests, statistics, prevention tips, and questions to help patients discuss prostate cancer with their doctors. For each download, ClevelandDx will donate to ZERO Prostate Cancer, with the nonprofit matching all donations in September.
Men are advised to begin discussing prostate cancer screening with their doctors at age 50, or 40 for those at higher risk. If no cancer is detected, regular screenings should occur every two years, or yearly for those with higher PSA levels. ClevelandDx initiated this campaign to educate about prostate cancer, the second most common and deadly cancer among American men, responsible for around 35,000 deaths annually. Earlier this year, the company secured $75 million in funding to expand its IsoPSA test and explore other cancer diagnostics.
Read the full article via FIERCE Pharma.
Search